Continuous Ketone Monitoring for the Safe Use of Sodium-glucose Cotransporter-2 Inhibitors in Type 1 Diabetes (R01 Clinical trial Required)

Go to Funding Search

Key Information

Due Date: June 27, 2024


Agency: Not Specified


Source: Federal


Funding Category:

Health & Human Services

Funding Amount: $500,000


Funding Type: Grant


Match Required: Yes


Contact Info: grantsinfo@nih.gov
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.

Overview

The goal of this grant, titled "Continuous Ketone Monitoring for the Safe Use of Sodium-glucose Cotransporter-2 Inhibitors in Type 1 Diabetes," (required R01 Clinical Trial), is to fund research that improves the safety and effectiveness of a specific type of medication, Sodium-glucose co-transporter-2 inhibitors (SGLT2i), for individuals with Type 1 Diabetes (T1D). SGLT2i, initially developed for Type 2 Diabetes (T2D), have proven to be beneficial in protecting against cardiac and renal diseases, applicable to both diabetic and non-diabetic individuals. However, they are not currently approved for T1D patients due to the elevated risk of diabetic ketoacidosis (DKA).

Despite this risk, growing numbers of T1D patients are being prescribed SGLT2i off-label. To ensure their safety, the integration of Continuous Ketone Monitoring (CKM) into clinical practice is encouraged. CKM is a newly emerging technology, promising to alert of heightened ketone levels, which can effectively prevent DKA.

The grant aims to fund studies designed to create and test risk reduction strategies. These strategies should incorporate CKM into the clinical application of SGLT2i for T1D patients, enabling them to safely benefit from the drug's cardiac and renal protective abilities, as well as its glucose-lowering effects. Successful applications will likely focus on short-term clinical trials aimed at further understanding and sharing knowledge on the safe application of CKM in combination with SGLT2i.

Applicants could focus on several potential topics, such as testing the most suitable insulin delivery methods (whether through open and closed loop systems or multiple daily injections), or formulating clinical protocols to manage or reduce high ketone levels in T1D patients who use SGLT2i as an additional treatment.

Show More

Key Dates

Open Date: January 30, 2024


Application Due Date: June 27, 2024


Estimated Award Date: Not Specified

Additional Details

Eligible Activities

  • Research and Development

Eligible Applicants

  • State governments
  • County governments
  • City, village or township governments
  • Special district governments
  • Independent school districts
  • Public and State controlled institutions of higher education
  • Native American tribal governments(Federally recognized)
  • Public housing authorities/ Indian housing authorities
  • Native American tribal organizations(other than Federally recognized tribal governments)
  • Nonprofits having a 501(c)(3) status with the IRS
  • other than institutions of higher education
  • Nonprofits that do not have a 501(c)(3) status with the IRS
  • Private institutions of higher education
  • For-profit organizations other than small businesses
  • Small businesses
  • Others

Search MI Funding Hub

NOTE: Site search does not include grant search. See Find Funding page for grant searching.